Heffernan Michael Thomas
Transaction: 06/03/2026
BUY
Change
+35,000
Price
$13.45
Filing
06/04/2026
Type
BUY
Trevi Therapeutics, Inc.
TRVI • Biotechnology
$17.26
▲ +0.20 (+1.17%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$2.70B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 19.66Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:00 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$17.26
Change1.17%
Shares Out156.60M
Market Cap$2.70B
Enterprise Value$2.38B
52W Range6.55 - 20.22
Beta1.00
P/E-52.89
P/B8.41
P/FCF-51.13
EV/EBITDA-45.16
EV/FCF-45.11
Price$17.26
Change1.17%
Shares Out156.60M
Market Cap$2.70B
Enterprise Value$2.38B
52W Range6.55 - 20.22
Beta1.00
P/E-52.89
P/B8.41
P/FCF-51.13
EV/EBITDA-45.16
EV/FCF-45.11
Earnings Yield-1.89%
FCF Yield-1.96%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio19.66
Quick Ratio19.66
Target$29.67
Target Upside71.90%
Target Median$27.50
Target Range23.00 - 40.00
Volume1.96M
Avg Volume2.08M
EPS Surprise-0.02
Investment DNA
How strong this company looks for long-term investors
34
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
21/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 19.66Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 18 analyst votes · 2026-09-05
100/100
Bullish
Bullish
18
Hold
0
Bearish
0
Price Target
2026-08-07
Low
$20.00
Mean
$30.00
Median
$30.00
High
$40.00
Insider Transactions
Recent executive and insider activity
⚠ 4 high-volume insider sells detected
VANLENT ANNE
Transaction: 06/03/2026
BUY
Change
+35,000
Price
$13.45
Filing
06/04/2026
Type
BUY
Meeker David P
Transaction: 06/03/2026
BUY
Change
+35,000
Price
$13.45
Filing
06/04/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Heffernan Michael Thomas | BUY | +35,000 | $13.45 | 06/03/2026 | 06/04/2026 |
| VANLENT ANNE | BUY | +35,000 | $13.45 | 06/03/2026 | 06/04/2026 |
| Meeker David P | BUY | +35,000 | $13.45 | 06/03/2026 | 06/04/2026 |
| Colangelo Dominick | BUY | +35,000 | $13.45 | 06/03/2026 | 06/04/2026 |
| Mathers Edward T | BUY | +35,000 | $13.45 | 06/03/2026 | 06/04/2026 |
| Simon Farrell | BUY | +160,000 | $10.56 | 02/19/2026 | 02/20/2026 |
| GOOD JENNIFER L | BUY | +675,000 | $10.56 | 02/19/2026 | 02/20/2026 |
| SCIASCIA THOMAS | BUY | +85,000 | $10.56 | 02/19/2026 | 02/20/2026 |
| Galletta Christopher | BUY | +35,000 | $10.56 | 02/19/2026 | 02/20/2026 |
| Cassella James V | BUY | +215,000 | $10.56 | 02/19/2026 | 02/20/2026 |
| Chang Carmen | OTHER | 0 | Not reported | 12/31/2025 | 02/13/2026 |
| Walker Paul Edward | OTHER | 0 | Not reported | 12/31/2025 | 02/13/2026 |
| Makhzoumi Mohamad | OTHER | 0 | Not reported | 12/31/2025 | 02/13/2026 |
| Behbahani Ali | OTHER | 0 | Not reported | 12/31/2025 | 02/13/2026 |
| Florence Anthony A. Jr. | OTHER | 0 | Not reported | 12/31/2025 | 02/13/2026 |
| SANDELL SCOTT D | OTHER | 0 | Not reported | 12/31/2025 | 02/13/2026 |
| Chang Carmen | SELL | -1,851,852 | $1.37 | 04/17/2025 | 02/13/2026 |
| New Enterprise Associates 16, L.P. | SELL | -1,851,852 | $1.37 | 04/17/2025 | 02/13/2026 |
| Walker Paul Edward | SELL | -1,851,852 | $1.37 | 04/17/2025 | 02/13/2026 |
| Makhzoumi Mohamad | SELL | -1,851,852 | $1.37 | 04/17/2025 | 02/13/2026 |